Glucagon-like peptide 1 (GLP-1) agonists, including exenatide, are promising agents for the treatment of type 2 diabetes. Exenatide, the first GLP-1 agonist to be Food and Drug Administration approved, and other members of this class of drugs have been shown to improve fasting and postprandial blood glucose and hemoglobin A~1c~ (A1C) and to promote weight loss, resulting in increased insulin sensitivity ([@B1]--[@B3]). Few reports have focused on GLP-1 agonist treatment in patients with type 1 diabetes. Herein, we report the effects of 6 months of therapy with exenatide in patients with long-standing type 1 diabetes focusing on outcomes related to glucose homeostasis, including fasting and postprandial blood glucose and insulin sensitivity, as determined by the reference glucose clamp method ([@B4]).

Research Design and Methods {#s1}
===========================

The current ancillary study to a clinical trial was conducted to ascertain whether exenatide could improve β-cell function in patients with long-standing type 1 diabetes ([@B2]). This study (clinical trial reg. no. NCT00064714, [clinicaltrials.gov](http://clinicaltrials.gov)) was performed at the National Institutes of Health in Bethesda, Maryland, after obtaining institutional review board approval. Written informed consent was obtained from all subjects. Twenty subjects (nine male) with long-standing type 1 diabetes (mean duration 21.3 ± 10.7 years) were enrolled, and their insulin treatment was optimized as previously reported ([@B2],[@B5]) ([Fig. 1](#F1){ref-type="fig"}). After a 3-month run-in period during which no further insulin dose changes were made, patients were randomized to continue insulin or insulin plus exenatide (with or without daclizumab) for 6 months, after which treatment assignment for exenatide was reversed. Exenatide was administered subcutaneously at a starting dose of 2.5 μg twice a day and gradually increased to 10 μg four times a day. Prandial insulin doses were reduced by 50% at the initiation of exenatide therapy and then gradually increased, with blood glucose goals of 80--140 mg/dL (home blood glucose monitoring was performed approximately seven times a day and recorded on an electronic worksheet).

![Study design and timeline for testing. Twenty patients with long-standing type 1 diabetes were enrolled, 14 completed both treatment periods, and 13 completed two hyperinsulinemic-euglycemic clamp studies at the end of periods A and B. Analyses focused on exenatide treatment. The interaction between exenatide and daclizumab was nonsignificant (*P* = 0.87); thus, the daclizumab and no-daclizumab groups were combined in the analyses of exenatide.](666fig1){#F1}

Thirteen of the 14 subjects who completed the trial participated in two 3-h hyperinsulinemic-euglycemic clamp studies, which were conducted at the end of the 6-month treatment periods on and off exenatide ([Fig. 1](#F1){ref-type="fig"}). These 13 subjects comprised the subgroup included in the present analyses. Subjects fasted overnight, and a basal insulin drip (Humulin; Eli Lilly, Indianapolis, IN) was adjusted to maintain euglycemia overnight. Glucose concentrations were maintained at 100 ± 10 mg/dL, and no insulin dose changes were made for 4 h before the clamp study. A cannula was placed into the dorsum of the hand, which was warmed with a heating blanket to 41°C to arterialize the blood. Insulin was infused at a constant rate of 120 µU/m^2^/min with a Razel calibrated syringe pump. After starting the insulin infusion, glucose analyses were performed every 5 min at the bedside with a blood glucose analyzer (YSI 2300 Stat; YSI, Yellow Springs, OH). Dextrose infusion (20%) was adjusted to maintain blood glucose at ∼90 mg/dL. The amount of glucose infused during the last 60--120 min of the clamp at steady state reflected the glucose disposal rate, which was normalized for body surface area and steady state clamp plasma insulin concentration to calculate an insulin sensitivity index (SI) expressed in mg/m^2^/min per µU/mL.

Statistical analyses were conducted with SAS Enterprise Guide version 5.1. Because 50% of subjects also received daclizumab, two-way ANOVAs were run to assess daclizumab treatment and its possible interaction with exenatide. Because the interaction was nonsignificant (*P* = 0.87), the daclizumab and no-daclizumab groups were combined in the analyses of exenatide. Mixed models (PROC MIXED) were used to determine changes in weight, fasting and postprandial glucose, A1C, and insulin requirements on versus off exenatide, assessing the effect of treatment order (exenatide first vs. second) as a covariate. There was no significant effect of treatment order for any outcome; thus, paired *t* tests were used to assess differences between on and off exenatide periods. Mixed models were used to assess change in SI on and off exenatide, adjusting for change in body weight. Data are reported as mean ± SD. *P* \< 0.05 was considered statistically significant.

Results {#s2}
=======

Baseline characteristics of the 13 subjects at enrollment are shown in [Table 1](#T1){ref-type="table"}. The mean age was 37.3 ± 10.7 years, and mean diabetes duration was 20.5 ± 11.8 years. Mean BMI was 26.1 ± 3.5 kg/m^2^, and mean A1C was 7.0 ± 0.8%. At the conclusion of the run-in period, weight was 77.7 ± 11.0 kg, A1C was 6.4 ± 0.7%, and insulin requirements were 0.55 ± 0.12 units/kg/day (0.31 ± 0.08 units/kg/day meal associated and 0.24 ± 0.09 units/kg/day basal). Exenatide use was associated with an average weight loss of 4.2 kg over 6 months (from 76.9 ± 11.3 kg off exenatide to 72.7 ± 11.8 kg on exenatide, *P* = 0.0003) ([Fig. 2*A*](#F2){ref-type="fig"}). Furthermore, A1C remained unchanged (6.7 ± 0.6% off vs. 6.6 ± 0.5% on exenatide, *P* = 0.39). Patients required significantly less insulin (from 0.54 ± 0.13 units/kg/day off exenatide to 0.47 ± 0.1 units/kg/day on exenatide, *P* = 0.007); this was a result of a reduction in meal-associated insulin (from 0.26 ± 0.09 units/kg/day off exenatide to 0.18 ± 0.05 units/kg/day on exenatide, *P* = 0.006) with no change in basal insulin requirements (from 0.29 ± 0.12 units/kg/day off exenatide to 0.29 ± 0.10 units/kg/day on exenatide, *P* = 0.57) ([Fig. 2*B*](#F2){ref-type="fig"}).

###### 
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![Changes in weight (*A*), insulin dosing (*B*), fasting and postprandial blood glucose (*C*), and insulin sensitivity (SI) (*D*) for each subject off exenatide (open bars) and on exenatide (solid bars). Data are mean ± SD.](666fig2){#F2}

As expected, exenatide therapy resulted in lower postprandial glucose concentrations (142.5 ± 4.4 mg/dL off exenatide vs. 135.5 ± 4.4 mg/dL on exenatide, *P* = 0.0005) but was associated with higher fasting plasma glucose (129.7 ± 3.2 mg/dL off exenatide vs. 136.9 ± 3.2 mg/dL on exenatide, *P* = 0.0002) ([Fig. 2*C*](#F2){ref-type="fig"}). SI increased from 5.21 ± 1.64 mg/m^2^/min per µU/mL off exenatide to 7.15 ± 2.05 mg/m^2^/min per µU/mL on exenatide (*P* = 0.0039) ([Fig. 2*D*](#F2){ref-type="fig"}). This 40% increase in insulin sensitivity remained significant after adjustment for body weight (*P* = 0.0076) and was independent of the sequence of treatment periods.

Conclusions {#s3}
===========

With exenatide therapy, we observed significantly lower postprandial glycemia despite a reduction in preprandial insulin doses. Postprandial glucose has emerged as a strong predictor of cardiovascular risk compared with fasting glucose ([@B6]). This effect mostly resulted from a slowing of gastric emptying ([@B2]). Unlike in subjects with type 2 diabetes and healthy volunteers ([@B7],[@B8]), we did not observe lower fasting glucose concentrations in the present patients, which might be explained by the inability of exenatide to effectively inhibit glucagon secretion with resultant unopposed hepatic glucose production ([@B9],[@B10]). We and others have shown a lack of glucagon suppression with exenatide ([@B1],[@B2]), which contrasts the findings of Dupré et al. ([@B3]). Possible explanations for the discrepancy among these studies are variable disease duration and duration of exenatide treatment.

Insulin resistance in type 1 diabetes has recently received more attention ([@B11]). Of note, 70% of the subjects had an initial SI at or below the cutoff for insulin resistance (5 mg/m^2^/min per µU/mL), and 85% had a marked improvement beyond what was expected as a result of weight reduction alone. This action of exenatide leading to improvement of whole-body insulin-mediated glucose utilization has previously been shown in animal models ([@B11]--[@B14]), but the exact mechanisms in humans remain unclear. Possible pathways include activation of phosphatidylinositol 3-kinase, leading to increased insulin-stimulated glucose uptake in muscle and fat concordant with results in L6 myoblasts and 3T3 adipocytes ([@B13]).

The present study is limited by its small sample size, higher doses of exenatide than typically administered in clinical practice, and subjects' excellent glycemia at baseline. We also did not differentiate between hepatic and peripheral insulin sensitivity by using stable isotopes in the clamp studies. Nevertheless, the observed effects of exenatide have potential clinical applicability. This pilot study suggests the need for further investigation to determine whether the improved insulin resistance we observed can be achieved with conventional doses of GLP-1 agonists. In summary, exenatide holds promise as an adjunctive agent to insulin therapy in patients with type 1 diabetes, mainly for its beneficial effects on postprandial blood glucose and insulin sensitivity.
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